Skip to main content

Day: January 5, 2021

OSS Wins Fourth Program with Major Military Contractor

ESCONDIDO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, has expanded its engagement at a major military prime contractor with its fourth major program win.This latest program, named “Orange Gear,” involves building an AI system consisting of a cluster of three OSS custom GPU-accelerated rugged servers. The server cluster has been designed to meet the unique power and ruggedization requirements of this airborne application. It is packed with the latest 200Gb Ethernet server-to-server networking, Gen 4 PCIe internal interconnects, NVMe storage devices, and third-party GPUs for edge AI acceleration.Computing and storage systems ruggedization pushes the requirements for ‘edge performance without compromise’ for AI applications to boundaries not...

Continue reading

ElectraMeccanica to Present at the 23rd Annual Needham Growth Conference on January 12, 2021

VANCOUVER, British Columbia, Jan. 05, 2021 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles, has been invited to present at the 23rd Annual Needham Growth Conference, which is being held virtually on January 11-15, 2021.ElectraMeccanica management is scheduled to present on Tuesday, January 12, 2021 at 5:00 p.m. Eastern time, with one-on-one meetings to be held throughout the conference. The Company’s presentation will be webcast live and available for replay here.For additional information or to schedule a one-on-one meeting with ElectraMeccanica management, please contact your Needham representative or Gateway Investor Relations at (949) 574-3860 or SOLO@gatewayir.com.About ElectraMeccanica Vehicles...

Continue reading

Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST.The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 30 days.About UltragenyxUltragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse...

Continue reading

Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

Agreement incorporates TYMLOS® and abaloparatide-TDConsideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royaltiesKey first step in expanding the global footprint for the abaloparatide asset beyond the U.S. and Japan; a key focus area for the company for 2021BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc. (“Paladin”), an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the terms of the...

Continue reading

Indus Holdings, Inc. Announces Kevin Lawrence as Chief Revenue Officer

Veteran cannabis, retail, and financial technology solutions executive to oversee revenue streams for California cannabis leaderSALINAS, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Indus Holdings, Inc. (CSE: INDS; OTCQX: INDXF), a leading, vertically-integrated cannabis company, has appointed Kevin Lawrence to the role of Chief Revenue Officer. Mr. Lawrence brings more than 25 years of leadership experience in the cannabis, retail, and financial technology solutions sectors to Indus Holdings, Inc., and will oversee all revenue streams for the organization, including marketing and sales operations.Mr. Lawrence most recently served as Vice President of Sales, Field Marketing, and Distribution for Flora California, Inc., one of the state’s largest licensed cannabis operators. Tasked with overseeing all purchasing, sales, distribution,...

Continue reading

Constellation Software Inc. Completes Spin-Out of Topicus.com Inc.

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) — Constellation Software Inc. (“Constellation”) (TSX:CSU) and Topicus.com Inc. (“Topicus.com”) announced today that Constellation, acting through its Total Specific Solutions (“TSS”) operating group and its subsidiary TPCS Holding B.V., has completed the previously announced purchase of 100% of the shares of Topicus.com B.V. (“Topicus”), a Netherlands-based diversified vertical market software provider, from IJssel B.V. and that in connection with the closing of the acquisition, TSS has been spun out of Constellation and now operates, together with Topicus, as a separate public company (collectively, the “Spin-Out Transactions”).In connection with the completion of the Spin-Out Transactions, on January 4, 2021, all of Constellation’s common shareholders of record on December 28, 2020 received,...

Continue reading

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100M.The PRV was granted to Rhythm by the U.S. Food and Drug Administration (FDA) with the approval of IMCIVREE™ (setmelanotide) for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing.“Rhythm is focused on transforming the care of people living with rare genetic diseases of obesity,” said...

Continue reading

Nucor Tubular Products Selects PowerFleet Telematics to Improve Steel Manufacturing Safety

Optimizing Lift Hardware and Instrument Crane OperationsWOODCLIFF LAKE, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) — PowerFleet, Inc. (Nasdaq: PWFL), a global leader and provider of subscription-based wireless IoT and M2M solutions for securing, controlling, tracking, and managing high-value enterprise assets such as material handling equipment, tractor trailers, containers, cargo, automobiles, and light and heavy duty truck fleets, announced today it has been selected by Nucor Tubular Products to improve safety, compliance, and utilization by using PowerFleet’s telematics solutions. Nucor Tubular Products has employed PowerFleet to enhance the safety of all warehousing operations at its facilities. After a rigorous pilot program, Nucor Tubular Products has chosen to deploy the PowerFleet Enterprise telematics solution across all...

Continue reading

Leading Healthcare Services Organizations Collaborate to Provide Innovative COVID Therapy Access Model

BATON ROUGE, La., and BANNOCKBURN, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, and Option Care Health Inc. (NASDAQ: OPCH), the nation’s largest independent home and alternate site infusion services provider, are collaborating on providing COVID antibody infusion therapy within skilled nursing and assisted living facilities, collectively referred to as “long term care facilities.” The U.S Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) to both Eli Lilly and Regeneron for their investigational neutralizing antibody therapies to treat mild to moderate COVID-19 in adults and pediatrics who are at high risk for progressing to severe COVID-19 symptoms or hospitalization.On December 8, 2020, the National Home Infusion...

Continue reading

Atlantic Union Bankshares Corporation To Release Fourth Quarter and Fiscal Year 2020 Results

RICHMOND, Va., Jan. 05, 2021 (GLOBE NEWSWIRE) — Atlantic Union Bankshares Corporation (the “Company”) today announced that it will release fourth quarter and fiscal year 2020 results before the market opens on Tuesday, January 26, 2021.Following the release, the Company will host a conference call and webcast for analysts at 9:00 a.m. Eastern Time on Tuesday, January 26, 2021.Management will conduct a conference call and listen-only webcast with accompanying slides, which can be found at: https://edge.media-server.com/mmc/p/ze3ax9o8 The conference ID is: 2886812A replay of the webcast, and the accompanying slides, will be available on the Company’s website for 90 days at: https://investors.atlanticunionbank.com/.About Atlantic Union Bankshares CorporationHeadquartered in Richmond, Virginia, Atlantic Union Bankshares Corporation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.